Claims

1. A use of a a combination of 5-aminosalicylic acid or a prodrug thereof that hydrolyses and/or metabolizes into 5-aminosalicylic acid, and one or more active substances selected from nicotinamide; a compound that converts in the body of an animal or human into nicotinamide selected from the group consisting of nicotinic acid esters and/or nicotinic acid; nicotinamide adenine dinucleotide (NAD); nicotinamide adenine dinucleotide phosphate (NADP); an intermediate in the biosynthesis of NAD or NADP selected from the group consisting of N-formylkynurenine, L-kynurenine, 3-hydroxy-L- kynurenine, 3-hydroxyanthranilate, 2-amino-3-carboxymuconate semialdehyde, quinolinate, and beta-nicotinate D-ribonucleotide; in the manufacture of a pharmaceutical composition, wherein the pharmaceutical composition releases one or both of the active substances for topical efficacy in the lower small intestine, the colon or both, and which is for use in therapy and/or prophylaxis of beneficially influencing the intestinal microbiota.

2. The use in the manufacture of a pharmaceutical composition for use in therapy and/or prophylaxis of claim 1, wherein the pharmaceutical composition is for use in therapy and/or prophylaxis of beneficially influencing the intestinal microbiota, wherein the pharmaceutical composition releases one or both of the active substances for topical efficacy in the terminal ileum, the colon or both.

3. The use in the manufacture of a pharmaceutical composition for use in therapy and/or prophylaxis of claim 1 or 2, wherein the pharmaceutical composition is for use in therapy and/or prophylaxis, comprising nicotinamide wherein the nicotinamide is released in the lower small intestine, preferably in the terminal ileum, the colon or both.

4. The use in the manufacture of a pharmaceutical composition for use in therapy and/or prophylaxis of claim 3, wherein the pharmaceutical composition is for use in therapy and/or prophylaxis for beneficially influencing the intestinal microbiota, wherein the pharmaceutical composition is comprising a combination of 5-aminosalicylic acid and nicotinamide, and wherein the pharmaceutical composition releases the active substances for topical efficacy in the terminal ileum, the colon or both.

5. The use in the manufacture of a pharmaceutical composition for use in therapy and/or prophylaxis according to any one of claims 1 to 4, wherein the pharmaceu-

tical composition is for oral administration with delayed release of the active ingredients for specific local effectiveness in the lower small intestine, preferably in the terminal ileum and/or colon.

6. The use in the manufacture of a pharmaceutical composition for use in therapy and/or prophylaxis according to any one of claims 1 to 5, wherein the pharmaceutical composition is formulated for oral administration with controlled release of the active ingredients for specific local effectiveness in the lower small intestine, preferably in the terminal ileum and/or colon.

7. The use in the manufacture of a pharmaceutical composition for use in therapy and/or prophylaxis according to any one of claims 1 to 6, wherein the pharmaceutical composition is for use in the therapy or prophylaxis of inflammatory diseases of the small intestine and/or diseases of the large intestine and/or for the use in prophylaxis of colon carcinoma; and/or for use in the therapy or prophylaxis of diseases that result from changes in the intestinal microbiota and/or an impaired interaction between intestinal microbiota and intestines; preferably wherein the pharmaceutical composition is formulated for oral administration and more preferably with delayed or controlled release.

8. The use in the manufacture of a pharmaceutical composition for use in therapy and/or prophylaxis according to any one of claims 1 to 7, wherein the pharmaceutical composition is for use in the (neo-rectal) administration in the colon or pouch for use in the therapy of inflammatory diseases of the large intestine or pouchitis.

9. The use in the manufacture of a pharmaceutical composition for use in therapy and/or prophylaxis according to claim 8, wherein the pharmaceutical composition is formulated for use in (neo)rectal administration in the colon or pouch.

10. The use in the manufacture of a pharmaceutical composition for use in therapy and/or prophylaxis according to claim 7, characterized in that the pharmaceutical composition is for oral application with an active substance content of 1–3000 mg of nicotinamide and 1–3000 mg of 5-aminosalicylic acid per finished dosage form, preferably characterized in that the pharmaceutical composition is for oral application with an active substance content of 10–1000 mg of nicotinamide and 10–1500 mg of 5-aminosalicylic acid per finished dosage form.

11. The use in the manufacture of a pharmaceutical composition for use in therapy and/or prophylaxis according to claim 8, characterized in that the pharmaceutical composition is for rectal application for the local therapy of inflammations in the rectum or pouch.

12. The use in the manufacture of a pharmaceutical composition for use in therapy and/or prophylaxis according to any one of claims 8, 9, and 11, characterized in that the rectal application is performed with an active substance content of 10–5000 mg of nicotinamide and 10–5000 mg of 5-aminosalicylic acid per finished dosage form.

13. The use in the manufacture of a pharmaceutical composition for use in therapy and/or prophylaxis according to any one of claims 1 to 12,

(a) for use in the therapy or prophylaxis of an inflammatory bowel disease, preferably ulcerative colitis or Crohn's disease or pouchitis,

(b) for use in the therapy or prophylaxis of colon carcinoma, or

(c) for use in the therapy or prophylaxis of diseases of body organs, which result from changes in the intestinal microbiota and/or an impaired interaction between intestinal microbiota and intestines.

14. The use in the manufacture of a pharmaceutical composition for use in therapy and/or prophylaxis of any one of claims 1 to 12, wherein the combination is for the manufacture of a pharmaceutical composition for administering in the same dosage form or in separate dosage forms or physically segregated in the same dosage form.

15. Use of the pharmaceutical composition for use in therapy and/or prophylaxis as defined in any one of claims 1 to 14, in the manufacture of a treatment regimen for administering the active substances simultaneously or sequentially.